Compare ERC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | EOLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.5M | 304.0M |
| IPO Year | N/A | 2018 |
| Metric | ERC | EOLS |
|---|---|---|
| Price | $8.85 | $4.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 73.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.37 |
| Revenue Next Year | N/A | $17.56 |
| P/E Ratio | $12.25 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $8.65 | $4.09 |
| 52 Week High | $9.78 | $13.10 |
| Indicator | ERC | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 42.49 |
| Support Level | N/A | $4.10 |
| Resistance Level | $9.47 | $4.99 |
| Average True Range (ATR) | 0.10 | 0.37 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 9.47 | 2.02 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.